ALKS Alkermes plc

50.54
-1.48  -3%
Previous Close 52.02
Open 52.18
Price To book 6.46
Market Cap 7765816542
Shares 153,656,837
Volume 674,134
Short Ratio 13.58
Av. Daily Volume 741,130

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17984685
  2. 8-K - Current report 17984427
  3. 8-K - Current report 17938355
  4. CT ORDER - Confidential treatment order 17907614
  5. 8-K - Current report 17866826

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiation announced June 8, 2017.
ALKS 3831 - ENLIGHTEN-Early
Schizophrenia - young adults
Pivotal trial initiated February 2016. Data due 2018.
ALKS 3831 - ENLIGHTEN-2
Schizophrenia
CRL received March 15, 2010.
BYDUREON
Type 2 diabetes
Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
Aristada
Schizophrenia
Phase 3 initiation announced March 16, 2017. Completion expected by end of 2017.
ALKS 8700
Multiple sclerosis (MS)
Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 6428
Opioid dependence
Phase 3 data from first two trials did not meet their endpoints. FORWARD-5 data, the third of three trials did meet endpoints - October 2016. Rolling NDA filing has commenced - noted August 21, 2017 with submission to be completed by end of 2017.
ALKS 5461
Major depressive disorder
Approved October 5 2015. sNDA filing due 2H 2016
Aristada
Schizophrenia
Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 3831 - ENLIGHTEN-1
Schizophrenia